Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Bacterial Capsules
Child, Preschool
Cost of Illness
Cost-Benefit Analysis
Haemophilus Infections
/ economics
Haemophilus Vaccines
/ economics
Health Care Costs
Humans
Immunization Programs
India
Infant
Infant, Newborn
Pneumococcal Infections
/ economics
Pneumococcal Vaccines
/ economics
Rotavirus Infections
/ economics
Rotavirus Vaccines
/ economics
Vaccination
Vaccines, Conjugate
/ economics
Diarrhea
Economics
India
Meningitis
Pneumonia
Savings
Vaccination
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
10 12 2019
10 12 2019
Historique:
pubmed:
15
10
2019
medline:
9
10
2020
entrez:
15
10
2019
Statut:
ppublish
Résumé
To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV). Based on variability in disease burden, strength of health system and economic status, we selected four states in India: Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs. By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range: US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states. Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings.
Sections du résumé
BACKGROUND
To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV).
METHODS
Based on variability in disease burden, strength of health system and economic status, we selected four states in India: Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs.
RESULTS
By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range: US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states.
CONCLUSIONS
Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings.
Identifiants
pubmed: 31607600
pii: S0264-410X(19)31326-X
doi: 10.1016/j.vaccine.2019.09.084
pii:
doi:
Substances chimiques
Haemophilus Vaccines
0
Haemophilus influenzae type b polysaccharide vaccine
0
Pneumococcal Vaccines
0
Rotavirus Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7547-7559Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.